

ResMed


myAir™

# Support better compliance rates with myAir

## Encourages 90-day compliance\*

# 2X

ResMed myAir™ users are 2x more likely to achieve 90-day, CMS-defined PAP therapy compliance\* than patients who don't use myAir.<sup>1</sup>



17% improvement in compliance\* (p < .0001) with myAir usage and AirView monitoring vs AirView monitoring alone.<sup>2</sup>

# 80%

## One-year compliance

80% of patients who reached compliance\* were still using their therapy at one year.<sup>1</sup>




## Daily therapy usage


myAir users averaged one additional hour of therapy use per night when they were also monitored in AirView.<sup>2</sup>

## Assistance with mask seal and leak†

- 3.5% improvement (p < .0001) in mask seal when myAir usage is paired with monitoring in AirView<sup>2†</sup>
- Average daily leak 16.9 L/min when myAir usage is paired with AirView monitoring<sup>2†</sup>
- 19.4 L/min when monitored in AirView alone<sup>2†</sup>




## myAir vs. Philips DreamMapper™: How do they stack up?




## 90-day CMS compliance\*

myAir usage combined with monitoring in AirView achieved a higher level of compliance than DreamMapper usage combined with EncoreAnywhere monitoring.



## Average nightly usage

myAir usage combined with monitoring in AirView achieved a greater level of usage than DreamMapper usage combined with EncoreAnywhere.



## Average residual AHI

myAir usage combined with monitoring in AirView achieved a lower residual AHI than DreamMapper usage combined with EncoreAnywhere.

Encourage your patients to download the myAir app<sup>‡</sup> or visit [ResMed.com/myAir](https://ResMed.com/myAir) for more info.

**Contact your ResMed sales representative to learn more.**

\* US Medicare compliance criteria: PAP use for ≥ 4 h per night on at least 70% of nights during a consecutive 30-day period during the first 90 days of initial usage  
 † ResMed defines an acceptable mask seal range as unintentional mask leak ranging from 12 – 24 L/min. ResMed threshold for high leak = 24 L/min or 36 L/min (nasal or oronasal mask).  
 ‡ The myAir by ResMed app is available in English in the US. The myAir for Canada by ResMed app is available in English and French in Canada.  
 1 Drager L et al., "Adherence with positive airway pressure therapy for obstructive sleep apnea in developing versus developed countries: a big data study" (sponsored by ResMed), *JCSM*, (Nov. 18, 2020), doi: 10.5664/jcsm.9008. n= 4,181,490. 2 Malhotra et al., "Patient engagement using new technology to improve adherence to positive airway pressure therapy: A retrospective analysis," *Chest* 153, no. 4 (Apr 2018): 843–850. 3 Philips Respironics' DreamMapper whitepaper: A retrospective EncoreAnywhere data analysis (2014-2016).  
 Distributed by ResMed Corp, 9001 Spectrum Center Boulevard, San Diego, CA 92123 USA. (858) 836-5000 or (800) 424-0737 (toll-free). See ResMed.com for other ResMed locations worldwide. AirView and myAir are trademarks and/or registered trademarks of the ResMed family of companies. DreamMapper, EncoreAnywhere and Philips are trademarks of Koninklijke Philips N.V, registered in the US and other countries. Specifications may change without notice. For patent and other intellectual property information, see ResMed.com/ip. © 2021 ResMed. 10112380/2 2021-07